<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03387566</url>
  </required_header>
  <id_info>
    <org_study_id>HB002.1M-01</org_study_id>
    <nct_id>NCT03387566</nct_id>
  </id_info>
  <brief_title>A Study of Single Intravitreal Injection HB002.1M in Subjects With Neovascular Age-Related Macular Degeneration</brief_title>
  <official_title>A Phase 1, Safety, Tolerability and Pharmacokinetic Profile Study of Intravitreous Injections of HB002.1M (a Vascular Endothelial Growth Factor Receptor Decoy) in Subjects With Neovascular Age-Related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huabo Biopharm Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Huabo Biopharm Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are to evaluate the safety, tolerability, and pharmacokinetic&#xD;
      profile of HB002.1M, a human immunoglobulin Fc fusion protein containing domain 2 and&#xD;
      flanking sequence of vascular endothelial growth factor (VEGF) receptor-1 in subjects with&#xD;
      age-related macular degeneration (AMD).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 8, 2018</start_date>
  <completion_date type="Actual">March 23, 2020</completion_date>
  <primary_completion_date type="Actual">February 1, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of AE (Adverse Effect), DLT (Dose Limit Toxicity) and MTD (Maximum Tolerance Dose)</measure>
    <time_frame>Up to 1 month after the single dose</time_frame>
    <description>Incidence of AE (Adverse Effect), DLT (Dose Limit Toxicity) and MTD (Maximum Tolerance Dose)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>T1/2 (Terminal phase half life) after single dose</measure>
    <time_frame>1 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax (maximum observed concentration) after single dose</measure>
    <time_frame>1 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC (Area Under Concentration-Time Curve) after single dose</measure>
    <time_frame>1 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity Evaluation after single dose</measure>
    <time_frame>2 months</time_frame>
    <description>Incidence of ADA(Anti-Drug Antibody) response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Best Corrected Visual Acuity (BCVA) from baseline</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in central retinal thickness from baseline by Optical Coherence Tomography (OCT)</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Choroidal Neovascularization (CNV) lesion area from baseline according to fluorescein angiogram</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of VEGF(Vascular Endothelial Growth Factor A) from baseline</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Neovascular Age-Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>HB002.1M 0.3mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a 0.3mg dose of HB002.1M via intravitreal (IVT) injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HB002.1M 0.5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a 0.5mg dose of HB002.1M via intravitreal (IVT) injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HB002.1M 1.0mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a 1.0mg dose of HB002.1M via intravitreal (IVT) injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HB002.1M 2.0mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a 2.0mg dose of HB002.1M via intravitreal (IVT) injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HB002.1M 3.0mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a 3.0mg dose of HB002.1M via intravitreal (IVT) injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HB002.1M</intervention_name>
    <description>HB002.1M is a Vascular Endothelial Growth Factor Receptor Decoy.</description>
    <arm_group_label>HB002.1M 0.3mg</arm_group_label>
    <arm_group_label>HB002.1M 0.5mg</arm_group_label>
    <arm_group_label>HB002.1M 1.0mg</arm_group_label>
    <arm_group_label>HB002.1M 2.0mg</arm_group_label>
    <arm_group_label>HB002.1M 3.0mg</arm_group_label>
    <other_name>Recombinant Human Vascular Endothelial Growth Factor Receptor-Immunoglobulin(IgG) Fc Fusion Protein Ophthalmic Injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Able and willing to provide written informed consent&#xD;
&#xD;
          -  Age 50 to 80 years old of either gender&#xD;
&#xD;
          -  Study eye must meet following requirements:&#xD;
&#xD;
               -  Active CNV lesions secondary to AMD&#xD;
&#xD;
               -  A lesion area &lt;30 mm2 (12 disc areas) of any lesion type&#xD;
&#xD;
               -  BCVA ranging from 73-19 letters (20/32-20/400 Snellen equivalent), inclusive&#xD;
&#xD;
               -  Clear ocular media and adequate pupil dilation to permit good quality&#xD;
                  photographic imaging&#xD;
&#xD;
          -  Fellow eye must have had BCVA of 19 letters ( 20/400 Snellen equivalent) or better&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Any ophthalmic condition as below:&#xD;
&#xD;
          -  Presence of non-exudative AMD in the study eye as determined by investigator that&#xD;
             affect macular examination, or presence of any diseases that affect central vision&#xD;
             (including central retinal vein occlusion, diabetic retinopathy, uveitis, vascular&#xD;
             fringes, pathological myopia, amotio retinae, macula hole etc.&#xD;
&#xD;
          -  Subretinal hemorrhage in the study eye the area of hemorrhage≥of total lesion area, or&#xD;
             hemorrhage in central fovea≥1 disc area&#xD;
&#xD;
          -  Presence of scar, fibrosis or atrophy in central fovea of the study eye&#xD;
&#xD;
          -  CNV of the study eye associated with other ocular conditions , such as pathologic&#xD;
             myopia, ocular histoplasmosis, posterior uveitis, or trauma&#xD;
&#xD;
          -  Anatomic damage to the center of the fovea including fibrosis and scarring making up&#xD;
             &gt;50% of total lesion area including the CNV in the study eye&#xD;
&#xD;
          -  History or presence of a retinal pigment epithelial tear, rhegmatogenous retinal&#xD;
             detachment or macular hole in the study eye&#xD;
&#xD;
          -  History of study eye with intraocular or any ophthalmic surgery within prior 3 months&#xD;
             (including Laser Photocoagulation at the para fovea , cataract etc.)&#xD;
&#xD;
          -  History of study eye with photodynamic therapy, macular translocation surgery&#xD;
             trabeculectomy, Recess photocoagulation, thermal laser or external beam radiation in&#xD;
             the study eye&#xD;
&#xD;
          -  History within 6 months of screening of following treatments(such as Macugen,&#xD;
             Lucentis, Avastin, Eylea, Conbercpet, steroids etc)&#xD;
&#xD;
          -  Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either&#xD;
             eye&#xD;
&#xD;
          -  Uncontrolled glaucoma in the study eye (defined as intraocular pressure of &gt;25 mmHg&#xD;
             despite treatment with maximal medical therapy)&#xD;
&#xD;
          -  History of any vitreous hemorrhage within 3 months&#xD;
&#xD;
        Any systemic conditions as below:&#xD;
&#xD;
          -  Currently or potentially using any drug that will cause ocular toxicity, such as&#xD;
             psoralen, risedronic acid; or tamoxifen etc.&#xD;
&#xD;
          -  Allergic to sodium fluorescein, indocyanine green, therapeutic or diagnostic protein&#xD;
             products, and allergic to ≥ two drugs or non-drugs, or with current allergic disease&#xD;
&#xD;
          -  Uncontrolled diabetes mellitus (fast glucose level ≥7.0 mmol/L or ≥11.1 mmol/L 2h&#xD;
             after meal)&#xD;
&#xD;
          -  History of surgery and/or unhealed wound, ulcer, fracture etc. 1 month prior to&#xD;
             screening&#xD;
&#xD;
          -  Any infectious disease requiring oral, intramuscular or intravenous administrations&#xD;
&#xD;
          -  History of Myocardial infarction and cerebral infarction within 6 months of screening&#xD;
&#xD;
          -  Active diffuse intravascular coagulation 3 months prior to screening&#xD;
&#xD;
          -  Systemic immunological diseases&#xD;
&#xD;
          -  Uncontrolled hypertension ≥150 mmHg systolic or ≥95 mmHg diastolic at baseline&#xD;
&#xD;
          -  Any severe or uncontrolled medical conditions (eg, unstable or progressive&#xD;
             cardiovascular, pulmonary, Parkinson, liver, or renal disease or cancer or dementia)&#xD;
&#xD;
        Any abnormal laboratory results as below:&#xD;
&#xD;
          -  Abnormal liver or kidney function test value (glutamic-oxalacetic transaminase(AST),&#xD;
             glutamic-pyruvic transaminase(ALT), creatinine(Crea), blood urea nitrogen(BUN) that&#xD;
             was more than 1.2 times of the upper limit of normal value)&#xD;
&#xD;
          -  Abnormal coagulation test(≥3 sec of upper limit value of prothrombin time, ≥10 sec of&#xD;
             upper limit value of activated partial thromboplastin time(APTT))&#xD;
&#xD;
          -  Positive in HbsAg, hepatitis C virus(HCV) antibody, human immunodeficiency virus(HIV)&#xD;
             antibody and syphilis antibody&#xD;
&#xD;
        Other conditions related to subjects with women of childbearing potential:&#xD;
&#xD;
          -  Without using any contraceptive method&#xD;
&#xD;
          -  Pregnancy or lactation (urine pregnancy test positive)&#xD;
&#xD;
        Others:&#xD;
&#xD;
          -  Participated clinical studies using any medications (not including vitamins and&#xD;
             minerals) 6 months prior to screening&#xD;
&#xD;
          -  Any assessment by the investigator to be unable to or unwilling to comply with&#xD;
             requirements of the protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Shanghai General Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>December 11, 2017</study_first_submitted>
  <study_first_submitted_qc>December 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">January 2, 2018</study_first_posted>
  <last_update_submitted>July 28, 2020</last_update_submitted>
  <last_update_submitted_qc>July 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Endothelial Growth Factors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

